Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea

1. Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success.

2. There were no serious or treatment-related adverse events in either group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Gepotidacin is a new antibacterial agent that may be effective in treating uncomplicated urinary tract infections. Given concerns over antibiotic resistance, alternative treatments for gonorrhea are needed. Additionally, gepotidacin can be administered orally, whereas current standard therapy includes both intramuscular and oral administration. This randomized controlled trial aimed to evaluate the efficacy and safety of oral gepotidacin versus intramuscular ceftriaxone plus oral azithromycin for uncomplicated urogenital gonorrhea. The primary outcome of this study was microbiological success, defined as eradication of Neisseria gonorrhea from the urogenital site, while the key secondary outcome was assessment of treatment safety. According to study results, gepotidacin was non-inferior to the standard treatment regarding the primary outcome but was associated with increased rates of mild-to-moderate adverse gastrointestinal events. Although this study was well-conducted, it was limited by a predominantly male population, which may affect its generalizability.

Click to read the study in The Lancet

Relevant Reading: Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea

In-depth [randomized controlled trial]: Between Oct 21, 2019, and Oct 10, 2023, 661 patients were screened for eligibility across 49 centers in 6 countries. Included were patients ≥ 12 years, weighing > 45 kg, with suspected urogenital gonorrhea confirmed by symptoms, lab testing, or both. Altogether, 628 patients (314 in both the gepotidacin and the standard ceftriaxone plus azithromycin regimen) were included in the final analysis. The primary outcome of microbiological success was comparable between the gepotidacin and standard treatment groups (92.6% vs. 91.2%), indicating non-inferiority. The secondary outcome of safety revealed slightly more mild-to-moderate gastrointestinal side effects in the gepotidacin group, but no serious or treatment-related severe adverse events in either group. Findings from this study suggest that oral gepotidacin is an effective and well-tolerated alternative to the current standard treatment for uncomplicated urogenital gonorrhea.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.